CEO, Co-founder, and Chairman of the Board of Directors

Dr. Linke, CEO and co-founder of SiVEC Biotechnologies, has secured $4 million in research funding, boasts 15 years of R&D experience in therapeutics and diagnostics, holds or has pending seven patents related to SiVEC technology, and possesses a Ph.D. in Infectious Disease Epidemiology and a Master's in Biomedical Engineering from Colorado State University. Dr. Linke has been recognized as an Inspiring Female Founder, a former US Olympic Swimming Trials qualifier and nine-time US Master's National Swimming Champion. As CEO, she has led SiVEC to several notable recognitions, including winning the 2022 Women in BIO Innovation Showcase and being named the 2022 Top Emerging Company at BIO International.

VP of Operations, Co-founder

Ms. Mora, Vice President of Operations and co-founder of SiVEC, has 12 years of experience in infectious disease and vaccine R&D, led development of over ten wildlife vaccines for the United States Department of Agriculture, and holds three pending and one allowed patent related to SiVEC technology. She earned a Masters in Veterinary Epidemiology and a Bachelor's in Biochemistry from Colorado State University.

Director of Research & Development

Dr. Williams, SiVEC’s Director of R&D, has over 15 years of experience in molecular biology and Escherichia coli genetics. His research background also spans many other key areas, ranging from molecular genetics and eukaryotic cell biology, to host-pathogen interactions, inflammatory responses, and oncology. Before joining SiVEC, Dr. Williams studied aging and aging-related diseases at the CECAD Research Center at the University of Cologne in Cologne, Germany. He holds degrees from Indiana University , including a Ph.D. in Microbiology, and completed post-doctoral fellowships at Harvard University and the University of Southern California.

Lead Research Scientist

As lead research scientist, Ms. Vivian brings over 8 years of experience in the development of anti-viral therapeutics. Prior to her work in the therapeutic space, she spent several years working on vaccine and analytical assay development at Takeda, Amgen, and the Centers for Disease Control and Prevention . She graduated from Colorado State University with a Bachelor’s degree in Microbiology.

Board Member

With over 25 years in global Pharma, including a 9-year tenure at Boehringer Mannheim/Roche, Ms. Hauser excels in corporate business development, fundraising, strategic planning, and international commercialization. Notably, she has focused on capital access and fundraising specialized in cell- and gene therapy technologies and precision medicine. As the former Executive Director, Innovation & Entrepreneurship at California Life Sciences, she focused on seed and series A capital raising. Additionally, she initiated and chaired the Women In Bio-Entrepreneur Center, connecting over 90 female founders with life sciences technologies across the US. She is a member of the Investment Committee of the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus.

Board Member

Dr. Sherris brings over 30 years of expertise in translational medicine, from basic research, pharmaceutics, and diagnostics. As a successful serial entrepreneur, he has built biotechnology companies from scratch, shaping strategy, implementing programs, and navigating funding and acquisitions. Dr. Sherris, a hands-on CEO, entrepreneur, and scientist, actively collaborates with venture capital firms, investment banks, and angel investors. His experience includes managing both external and internal research and development for pharmaceutical and biotech companies. A respected speaker at biopharmaceutical conferences, published author, and holder of patents across therapeutic areas, Dr. Sherris has held key roles in public and private companies, overseeing drug development, fostering partnerships, and raising capital.

Scientific Advisory Board

Dr. Wyckoff, an Immunologist with 33 years of research experience, has past positions in R&D leadership at major global companies, including Merial, Boehringer Ingelheim, and Elanco. Most recently, he was the Director of BioMARC, a biopharmaceutical CDMO. Dr. Wyckoff serves as a Scientific Advisor to SiVEC Biotechnologies, offering expertise in scale-up and production of biologics and biotherapeutics, process development and analytical evaluation, study design, licensing, regulatory readiness, and partnerships.

Scientific Advisory Board

Dr. Goovaerts, with extensive experience in vaccine R&D and therapeutic drug development, previously led R&D at Intervet (Merck) and now provides global consulting on health related topics. He serves as a scientific advisor to the Bill and Melinda Gates Foundation, the Wellcome Trust, and the Food and Agriculture Organization (FAO). He offers SiVEC Biotechnologies valuable insights into biologics and product development, global regulations, research strategy, and international licensing.